Welcome to the EAASM website  

Contact us at enquiries@eaasm.eu to share your experiences of buying medicines online, or receiving medicines from your pharmacist which have seemed out of the ordinary.

The European Alliance for Access to Safe Medicines (EAASM) is an independent, pan-European initiative dedicated to protecting patient safety by ensuring access to safe and legitimate medicines. The Alliance was formed by a cross-section of European stake-holders from a variety of backgrounds. Its key activities include campaigning for the safer use of unlicensed or off-label medicines and also the exclusion of counterfeit and substandard medicines from the supply chain, raising public awareness around such issues, and promoting effective legislation and enforcement in relation to falsified medicines. For a leaflet summarising the EAASM's activities and achievements click here

On this website you will find a wealth of information about counterfeit and substandard medicines. Our top tips section will help you to reassure yourself that the prescription medicine you are buying is genuine. Our news section will provide you with the latest news on counterfeit medicines in Europe and around the world as well as updates about the EAASM activities. The EAASM constantly updates and adds useful resources to the website so you can get as much information as possible about obtaining safe medicines.

Latest News

New Report Demonstrates Significant Resources Required to Implement FMD into Hospital Setting

22 Mar 2019

Resources needed to implement the Falsified Medicines Directive in hospitals across the EU and the EEA would cost more than 86 million euros, according to estimates.

The recent report (March 2019) of the European Alliance for Access to Safe Medicines (EAASM) highlights the significant added value that the final patient safety elements of the Falsified Medicines Directive will bring. The Directive requires that every single prescription pack is serialized and has a unique identifier in the form of a barcode and a tamper evident seal. Each pack will need to be verified and decommissioned before it can be dispensed thus confirming the pack is genuine and not falsified.

Invitation Breakfast Meeting - Handling innovation in NANOMEDICINES: regulatory challenges and opportunities in modern healthcare

19 Mar 2019

Nanomedicines are an emerging product class in the health sector which has been gaining increasing attention in academia and research over the past twenty years. It has the potential to provide personalised, yet more affordable, healthcare while at the same time offering better quality of life for the sick and injured, opening up numerous potential pathways to improving medical diagnosis and therapy. However, there is a need to establish robust regulation that is fit for purpose, such as the creation of harmonised definitions across Europe and development of protocols for their characterization, evaluation and pharmacovigilance oversight once an NCE is marketed.

Roundtable “Improving patient safety with the FMD in the hospital pharmacy, status of implementation” 19 February 2019, EU Parliament

22 Feb 2019

The manufacture and distribution of falsified medicines has become an enormous, serious public health risk with an untold cost to lives.

On 9 February 2019, almost 7 years after its adoption, the final elements of the Falsified Medicines Directive (FMD) came into force introducing the end-to-end verification and safety features on prescription medicines across all Member States, representing a major advance to in patient safety due to the enhanced security of medicines in the supply chain.